Search research articles
Contact Us
Filters
Showing results (111-120 of 157) with videos related to
Page
of 16
Sort By:
JCO Precision Oncology
|
March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes
Reva K Basho, Li Zhao, Jason B White, et al.
European Journal of Radiology
|
February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer
Jorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
Ana M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant
Jennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 6, 2019
The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists
Carmen Bergom, Catharine M West, Daniel S Higginson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2020
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Nadine M Tung, Judy C Boughey, Lori J Pierce, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 28, 2021
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing
Bhavana V Chapman, Diane Liu, Yu Shen, et al.
Oncotarget
|
November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
Reva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 5, 2021
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation
Bhavana V Chapman, Diane Liu, Yu Shen, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 157) with videos related to
Sort By:
Page
of 16
JCO Precision Oncology
|
March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes
Reva K Basho, Li Zhao, Jason B White, et al.
European Journal of Radiology
|
February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer
Jorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
Ana M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant
Jennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 6, 2019
The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists
Carmen Bergom, Catharine M West, Daniel S Higginson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2020
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Nadine M Tung, Judy C Boughey, Lori J Pierce, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 28, 2021
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing
Bhavana V Chapman, Diane Liu, Yu Shen, et al.
Oncotarget
|
November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
Reva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 5, 2021
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation
Bhavana V Chapman, Diane Liu, Yu Shen, et al.
Page
of 16